- Relugolix had a similar rate of castration resistance-free survival in the subgroup of men with metastatic disease compared to leuprolide acetate (74% vs. 75%, respectively) and did not achieve statistical superiority (p = 0.84)
- Relugolix is under Priority Review with an FDA target action date of December 20, 2020, supported by positive Phase 3 HERO study results including a 97% responder rate and six positive key secondary endpoints
San Francisco, CA (UroToday.com) — Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer. Relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks.